Redeye

Mendus: Phase III Win for AML Vaccine Supports Vididencel

Källa: MFN
Osäker

Redeye’s analyst just published a Research Note on Mendus.Click here to read the articleMake sure to add Mendus to your Watchlist at Redeye and our analysts will notify you if anything relevant happens regarding your companies

About Redeye Nordic Growth AB

This is a press release from Redeye Nordic Growth AB, a equity research firm specializing in Nordic growth companies within Tech and Life Science. Redeye Nordic Growth is a part of the Redeye group, which also offers services within corporate finance advisory and fund management. https://services.redeye.se/

Attachments

Mendus: Phase III Win for AML Vaccine Supports Vididencel